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ABSTRACT  
 
Cytogenetic studies were performed on 80 pediatric cancer patients to observe the 
chromosomal damage, both quantitative and qualitative, induced by chemotherapy. 
Peripheral blood lymphocytes (PBL) (n = 127) were obtained at diagnosis, during 
treatment, at remission, and at relapse, and chromosome analysis performed utilizing G-
banding standard procedures. The results show a significant increase in the number of 
altered karyotypes (P = 0.03) in the samples during treatment, returning to values that 
were similar to those at diagnosis at 2-year remission. Most of the chromosomal 
aberrations (CA) detected during the chemotherapy regimens were nonclonal, 
unbalanced (75%), and involved chromosomes 1, 3, 5, 6, 11, 12, 16, and 17 most 
frequently. There was also a marked increase of CA in samples at relapse with very 
similar features (type and distribution) to those detected during treatment. There was a 
good correlation between the chromosomal breakpoints in our series and fragile sites 
(58%), oncogene (75%), and tumor suppressor gene (33%) loci described in the 
literature. The results obtained suggest that cytostatic drugs induce a transient increase 
in chromosome fragility occurring at several cancer-associated breakpoints.  
 
  
 
 
 
 
 
INTRODUCTION 
 
Analysis of chromosomal aberrations (CA) in peripheral blood lymphocytes (PBL) has 
been extensively used in the biomonitoring of populations exposed to genotoxic 
environmental agents. Various authors, based on the hypothesis that the genetic damage 
in PBL reflects similar events for carcinogenic processes in target tissues, have 
demonstrated that an increased frequency of CA is often indicative of increased cancer 
risk [1, 2]. Based on this evidence, chromosomal studies in cancer patients can be 
considered as a suitable and reliable method of monitoring the genotoxicity of chemical 
agents used in therapeutic regimens. 
 
Many of the cytostatic drugs induce chromosomal damage [3] and the leukemogenic 
potential of antineoplasic agents is well known [4]. The number and nature of genetic 
changes occurring in samples obtained from patients bearing tumors, prior to any 
treatment, are well documented [5]. Although the increase in CA related to chemo-
therapy has been reported previously [6, 7], not only the increase in frequency, but also 
the type and distribution of structural CA may be important. Several reports have shown 
that chromosome breakage induced by various mutagens and carcinogens coincides, to a 
great extent, with the location of cancer breakpoints [8]. A majority of mapped 
oncogenes are located at these breakpoints and some of them are known to be activated 
following chromosomal rearrangements. Fragile sites have also been implicated, 
because they mostly involve the same bands as cancer breakpoints or those near to 
oncogene and tumor suppressor gene loci [9–11]. 
 
The aim of the present study was not only to test if the CA frequency increases due to 
the antitumoral regimens, but also to analyze its persistence throughout clinical 
remission. We also intended to determine if CA preferentially occur in those bands that 
harbor cancer-related genes or fragile sites. 
 
 
 
MATERIALS AND METHODS  
 
Patients and Samples 
 
Eighty pediatric cancer patients were included in the chromosomal analysis, and 
classified into four tumoral types: 22 Ewing sarcomas (ES), 32 osteosarcomas, 13 
lymphomas, and 13 central nervous system (CNS) tumors. 
 
Peripheral blood samples (n = 127) were scheduled as follows: 11 at diagnosis, 37 at the 
end of treatment, 38 at short-term remission (between the first and second year after the 
end of treatment), 31 at long-term remission (more than 2 years after treatment), and 10 
at relapse. 
 
The chemotherapy received by our patients is indicated in Table 1, in which the 
cytostatic agents have been classified according to their mechanism of action. 
Cytogenetic studies were performed on peripheral blood samples following standard 
procedures. A minimum of 50 well-spread metaphases, obtained from 72-hour 
phytohemagglutinin-stimulated cultures, were analyzed. Chromosomal abnormalities, 
identified by G-banding, were described according to the ISCN 1995 [12]. 
Statistical analyses involved the Chi-square contingency test, the Fisher’s exact test, or 
the Kruskal-Wallis, depending on the type of variables analyzed and on the fulfillment 
of the normality criteria. Statistical significance was assumed if P ≤ 0.05, and highly 
statistically different if P < 0.01 and differences between variables with P > 0.05 were 
considered not statistically different. The software used for the statistical analysis was 
the Statistical Package for the Social Sciences (SPSS, version 9.0). 
 
 
RESULTS 
 
We analyzed chromosomal aberrations induced by cytostatic agents used in 
chemotherapy regimens in 80 pediatric cancer patients. Seventy of the 127 samples 
(55.1%) showed altered karyotypes. There were no statistical differences in the number 
of samples with chromosomal aberrations between the four tumoral groups considered. 
Nevertheless, the number of aberrant karyotypes was higher in the lymphoma and ES 
groups (P = 0.07). 
 
Statistical differences were detected in the number of samples with aberrant karyotypes 
throughout the different stages of the chemotherapy. Chromosomal aberrations most 
frequently appeared in the relapsed tumors (80%, P = 0.05) and in the samples obtained 
during treatment (64.8%, P = 0.03) (Table 2). 
 
All CAs detected in our series were nonclonal, except in four cases: a Hodgkin 
lymphoma at diagnosis (46,XY, -5,+der[13]t[13;14][p10;p10]), an osteosarcoma at 
short term-remission [case no. 3, Table 3: 46,XY,inv(9)(p13q22)], and two CNS tumors 
during treatment [case no. 21 in Table 3: 46,XX,del(5)(p12),del(6)(q14),del(17)(p13); 
and case no. 18 in Table 3: 46,XY,t(5;9)(q11;p23)], in which clonal aberrations were 
detected (defined as at least two cells with the same extra chromosome or structural 
rearrangement or three cells with the same missing chromosome). 
 
When considering the type of CA, we found again that there were no significant 
differences among tumor types; however, the distribution of unbalanced CA was 
different in the various stages considered; significantly increasing during treatment and 
at relapse (Table 4). Most patients displayed very complex karyotypes, frequently 
during treatment and at relapse (Fig. 1). We recorded 275 alterations in 70 aberrant 
karyotypes (Table 3), thus yielding a mean number of 3.9 alterations per karyotype that 
was statistically higher (P = 0.02) in the group of samples during treatment (mean 5.5) 
and at relapse (mean 5.26). 
 
To convey the essential karyotypic features in a more comprehensive manner, we 
illustrated our findings in patients at the end of the treatment and at short-term 
remission in a breakpoint map (Fig. 2). We detected a total number of 134 aberrations in 
the samples obtained during treatment, 30 of them were balanced and 104 unbalanced. 
The CA did not follow a random pattern, and the most frequent aberrations were losses 
affecting mostly chromosomes 2, 10, and 22 (Fig. 3). The most frequently encountered 
chromosomal breakpoints were 1p13 and 1q25, 3p21 and 3q21–q23, exclusively found 
in osteosarcomas and ES, 5q11, and 5q31–q35, 6q21–q23, 11p15, 12q13, 16q22–q24, 
and 17p13 and 17q21. These breakpoints were correlated with the location of fragile 
sites (7/12, 58%), tumor suppressor genes (4/12, 33%) and especially with those of 
oncogenes (9/12, 75%) (Table 5). 
 
Up to 80% of the patients who relapsed showed altered karyotypes with features very 
similar to those of patients undergoing chemotherapy. 
 
 
DISCUSSION 
 
The study of lymphocyte cultures has shown that healthy persons can bear CA in a very 
low percentage of cells, between 0–2% [13]. Our data suggest that there is a higher 
frequency of altered karyotypes in pediatric cancer patients in comparison to healthy 
children, before as well as after treatment. 
  
Due to the heterogeneous antitumoral regimens received, it is difficult to determine the 
effect of individual drugs, or even that of radiotherapy, on chromosomes. This may 
account for the fact that no significant differences were found between the four tumoral 
groups analyzed, either in frequency or in the type of CA present, regardless of the 
combination of drugs and of whether they received radiotherapy (ES, CNS tumors, and 
lymphomas) or not (osteosarcomas). 
 
In agreement with other authors [3, 6, 7], we detected a marked increase of nonclonal 
chromosomal alterations at the end of treatment, returning to normal values in the 
months following treatment. In this study, similar CA values were recorded for samples 
before treatment and at long-term remission, although they were still higher than those 
observed for the general healthy population [13]. 
  
The fact that up to 80% of relapsed patients showed altered karyotypes supports the idea 
that the chromosomal aberrations are the consequence of an underlying genomic 
damage, and therefore, their frequency would increase in periods of higher genetic 
instability. 
 
Not only the increase in the frequency of structural CA, but also their type and 
distribution are important. We found that the aberrations induced by the mutagenic 
agents are mostly of the chromatid type, showing a nonrandom distribution pattern. The 
patients’ karyotypes tended to be very complex, most often for those during treatment 
and at relapse, when the CA frequency doubled to that of samples at diagnosis or at 
long-term remission (Table 4). 
 
Two distinct neoplasia-associated karyotypic patterns have been defined recently [14]. 
Primary abnormalities are believed to be essential in establishing the tumors, while 
secondary abnormalities occur in addition to the primary, and are important in tumor 
progression and maintenance. Primary abnormalities consist of balanced structural 
chromosomal rearrangements, mostly translocations and some inversions, and are more 
specific than secondary or unbalanced rearrangements, deletions, and chromosome 
losses. It is important to point out that in this study, a significant in-crease of 
unbalanced abnormalities, mostly chromosome losses, has been detected in samples at 
the end of treatment and at relapse, accounting for 75% of all CAs detected. Some 
authors [14, 15] suggest that chemotherapy is an important factor in determining which 
subclones with secondary aberrations will appear at remission. In contrast to the 
balanced abnormalities, the molecular consequences of the recurrent unbalanced 
abnormalities are unknown to date. 
The CA induced by treatment show a nonrandom distribution pattern. Chromosome 
losses are the most frequently encountered aberrations in our patients, especially 
involving chromosomes 2, 10, and 22. The breakpoints mapped, most frequently, in 
chromosome bands 1p13, 1q25, 3p21, 3q21–q23, 5q11, 5q31–q35, 6q21–q23, 11p15, 
12q13, 16q22–q24, 17p13, and 17q21 (Fig. 2). 
 
Chromosomes 5 and 7 are preferentially involved in secondary AML cases following 
alkylating therapy and chromosome band 11q23 in topoisomerase-associated secondary 
AML [4, 16]. Losses of chromosomes 5 and 7 have been defined as common indicators 
of insults to DNA induced by radiation, alkylating agents, or by occupational exposure. 
In our series, loss of both chromosomes 5 and 7, as well as alterations of 5q (mostly the 
q31–q35 region), were among the most frequently observed CA. We did not detect 
rearrangements at 11q23, and the most frequent breakpoint in our patients was 11p15; 
we assume that it may be due to the scarce use of topoisomerase inhibitors in the 
chemotherapy regimens of these patients. Rearrangements of 11p15 have been reported 
in several childhood and adult tumors and as a nonrandom anomaly of therapy-related 
myeloid leukemia in children, in contrast to adults [17]. Involvement of the 11p15 has 
been described in osteosarcoma secondary to irradiation, suggesting that a fragile site is 
located at this region, and that radiation or chemotherapy (in our series) may induce 
chromosome breakage at this band [18]. It is also noteworthy that several oncogenes 
and tumor suppressor genes map to 11p15 [10, 11]. 
  
Structural abnormalities of chromosome 3 were frequently encountered in our patients. 
The most frequently involved bands were 3q21–q23 and 3p21, which have been 
reported as recurrent treatment-related breakpoints in myelodysplastic syndrome and 
acute myeloid leukemia [17, 19]. 
 
Rearrangements of 6q21–q23, 12q13, and 17p13 have been observed in several solid 
tumors, and chromosome 17 anomalies have been reported to be increased in patients 
receiving chemotherapy or radiotherapy [16]. 
 
It appears that the chromatin within certain bands may be especially susceptible to 
damage by any number of chemical agents and the fragile sites may also contribute to 
this special distribution of CA. There is a highly significant statistical association 
between the location of fragile sites and cancer breakpoints [20]. Individuals with rare 
fragile sites (11q13, 12q13, 16q22) in PBL have been reported in the literature who had 
a breakpoint apparently coincident with a fragile site present in their cancer cells [21]. 
In our study, a relationship possibly existed between the most frequently observed 
chromosomal breakpoints and fragile sites, oncogenes, and tumor suppressor gene loci 
described in the literature [9–11] (Table 5). 
 
We conclude from the present study that an increased incidence of nonclonal CA is a 
typical finding in lymphocytes from children exposed to antitumoral regimens. This 
incidence tends to decrease in the months following the end of chemotherapy, reaching 
similar values to those at diagnosis at 2-year remission. The CAs are mostly of the 
chromatid type and unbalanced aberrations, and the most frequently involved bands are 
associated with fragile sites, oncogene and tumor suppressor gene loci. 
 
Although there is a marked increase of CA at relapse, there is no sufficient data, 
however, to conclude if the chromosomal damage is predictive of relapse or secondary 
tumor development at the level of the individual patient. The molecular consequences of 
these secondary aberrations and its putative relationship with tumoral progression are 
yet to be elucidated. 
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 Table 1. Types of treatment received by the patients included in this study 
Tumor Group Aa Group Bb Group Cc Group Dd Radiotherapy
ES + + + + + 
Osteosarcoma + + + + — 
Lymphoma + + + + + 
CNS tumor + — + + + 
Abbreviations: ES, Ewing sarcoma; CNS, central nervous system. 
aAlkylating agents (cyclophosphamide, ifosfamide, CCNU, BCNU), cisplatin and 
procarbazine. 
bCytostatic antibiotics (actinomycin D, adriamycin, bleomycin, daunomycin). 
cAntimetabolites (methotrexate, cytosine arabinoside). 
dSpindle inhibitors (vincristine, vinblastine). 
 
 
 
 
Table 2. Patient karyotype status before, during, and after treatment 
Stage No. of samples (n)
Normal 
karyotype
aAbnormal 
karyotype 
bProbability 
(P) 
Diagnosis 11 7 4 (36.4) 0.36 
Treatment 37 12 24 (64.8) 0.03 
Short remission (<2 years) 38 16 22 (57.9) 0.33 
Long remission (>2 years) 31 19 12 (38.7) 0.2 
Relapse 10 2 8 (80.0) 0.05 
Total 127 56 70 (55.1) 0.04 
aNumbers in parentheses refer to the percentage of altered karyotypes in each of the 
stages. 
 
bChi-square contingency test: not significant P > 0.05, statistically significant P ≤ 0.05, 
highly statistically significant P < 0.01. 
 
 
 
 
 
 
 
 
 
 
Table 3 Description of abnormal karyotypes detected in the samples obtained during 
chemotherapy and at short-term remission 
Case 
no. Tumor Abnormal karyotype (at short-term remission) 
1 OS 46,XY,del(16)(p11.2) 
2 Burkitt 48,XY,del(1)(q32),del(3)(p21),add(4)(q35),+2mar 
3 OS 46,XY,inv(9)(p13q22) 
4 ES 46,XX,del(17)(p13) 
5 HL 46,XX,t(7;12;15)(q22;q14;q22) 
6 CNS 47,XX,-2,-6,add(12)(q13),+3mar/43,X,-X,der(5)t(1;5)(q25;q22), del(9)(q22),    -16, -19,del(20)(q11)/46,XX,+del(1)(p23),-6 
7 ES 47,XX,+del(12)(p13) 
8 OS 46,XX,del(X)(q13)/46,XX,t(1;9)(q25;q22) 
9 ES 46,XY,+8,-14,+add(20)(q13),-21 
10 CNS 46,XY,add(16)(p13) 
11 NHL 46,XX,t(3;6)(q21;q22)/46,XX,t(5;8)(q34;q12)/46,XX,del(3)(p21)/46, XX,t(2;4)(p15;p13) 
12 ES 46,XX,t(10;20)(q22;q13) 
13 ES 46,XX,t(18;18)(p11.1;q11)/46,XX,del(11)(p13) 
14 ES 46,XY,+8,-13,del(16)(q13)/46,XY,t(4;5)(q26;q22) 
15 HL 46,XX,t(1;3)(p31;q12) 
16 CNS 46,XX,t(5;13)(q11;q34)/46,XX,-2,+15 
17 OS 46,XY,t(2;7)(q31;p15) 
18 CNS 46,XX,t(1;14)(q43;q11),add(16)(p13) 
19 ES 46,XY,inv(11)(p15q13) 
20 OS 46,XX,del(2)(q23) 
21 CNS 49,XY,add(2)(p24),-4, t(7;15)(p13;q11), del(10)(p12), add(16)(q24), +20,+3mar/46,XY,del(1)(q32),add(17)(p13)/46,XY, t(1;7)(p31;q34) 
22 ES 45,XY,add(1)(p13),-8,-11,-22,+2mar 
  Abnormal karyotype (during treatment) 
1 CNS 47,XX,-18,+2mar 
2 OS 48,XY,del(3)(q25),+r,+mar/47,XY,del(5)(q11q33),+r 
3 ES 46,XY,del(3)(q23)/46,XY,t(3;6)(p25;p21.2)/46,XY,t(3;19)(p22;q13);46,XY,del(11)(q14)/46,XY,-8,+del(9)(q31),der(14) t(10;14)(q23;?) 
4 ES 46,XX,t(4;7)(q35;q22)/46,XX,dic(3;5)(q23;q35) 
5 OS 46,XY,add(8)(q13) 
6 ES 44,Y,-X,-8/46,XY,del(3)(p23),i(21)(q10) 
7 CNS 44,Y,-X,t(1;20)(p13;q11),-6/47,XY,+dic(1;6)(p21;q24),-2,-16,+2mar 
8 OS 46,XX,del(9)(q11) 
9 ES 
46,XY,t(2;17)(p23;q24)/46,XY,-2,del(3)(q21),-7,add(8)(p23),+2mar/48, XY, 
add(1)(q21),-13,add(16)(p13),+3mar/46, XY, dup(1)(q31q32),dic(1;21) 
(q43;q22),del(5)(q31q33),del(8)(q21),der(11)(p15),-13,+add(15)(q24), add(16)(q24)
10 OS 48,XY,i(1)(p10),+2/46 XY,-2,+20 
11 OS 
46,XY,-2,add(3)t(3;?)(p13;?),add(11)(p11.2),+mar/47,XY,der(1)t(1;4)(q41;p16),-3,   
-4,del(7)(q21),dic(10;?)(q24;?),-10, add(14)(q32),dic(16;20)(q22;q13), +4mar/46, 
XY,del(6)(q22) 
12 OS 46,XY,t(4;12)(q12;q13)/46,XY,t(5;12)(q31;q21)/47,XY,del(1)(p22),t(2;11)(q11;p15),del(6)(q23),-7,der(7)t(1;7)(q25;p15), +mar 
13 CNS 45,XX,+der(1)t(1;18)(p13;q23),-2,add(11)(p15),der(16)t(2;16)(q21;q24),        -18/45,XX,-12,add(17)(q21) 
14 OS 45,XY,-22/44,X,-Y,del(1)(p32),+der(2),-10,-10,add(11)(p15),add(14)(q11),    -15,-18,+2mar 
15 ES 46,XY,del(1)(p13),-3,-16,+2mar 
16 OS 45,XX,-16/46,XX,+9,-10,+11,-19 
17 NHL 46,XY,t(2;17)(q24;q21)/46,XY,t(1;15)(q22;p11) 
18 CNS 46,XY,t(5;9)(q11;p23) 
19 ES 45,XY,-4,-5,-22,-22,+3mar 
20 CNS 46, XX,del(5)(q31q33)/47,X,-X, 10,add(11)(q22),der(17)t(10;17)(p14;q24),      -22,+4mar 
21 CNS 46,XX,add(16)(q?)/46,XX,del(5)(p12),del(6)(q14),del(17)(p13)/46,XX,del(6)(q14q21)/46,X,add(X)(q28),add(2)(q24),-5, del(17)(p13),add(20)(q13),+mar 
22 NHL Complex karyotype 
23 ES 46,XY,inv(11)(p15q13) 
24 CNS 46,XX,del(12)(q13) 
Abbreviations: OS, osteosarcoma; ES, Ewing sarcoma; HL, Hodgkin lymphoma; CNS, central 
nervous system tumor; NHL, Non-Hodgkin lymphoma. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4. Number and type of chromosomal alterations detected in the different stages              
of the evolution considered 
Stage 
Altered 
karyotypes 
aP = 0.04 
bc 
Total no. 
of 
aberrations
P = 0.02 
cn (n/c) 
Balanced
P = 0.81 
n (n/c) 
Unbalanced
P = 0.05 
n (n/c) 
Translocations 
P = 0.80 
Deletions
P = 0.40
Losses 
P = 0.06
Diagnosis 4 9 (2.2) 3 (0.7) 6 (1.5) 3 0 3 
Treatment 24 134 (5.5) 30 (1.2) 104 (4.3) 21 23 46 
SR 22 62 (2.8) 16 (0.7) 46 (2.8) 15 16 16 
LR 12 28 (2.3) 10 (0.8) 18 (1.5) 9 7 8 
Relapse 8 42 (5.2) 9 (1.1) 33 (4.1) 8 1 13 
Total 70 275 (3.9) 68 (0.9) 207 (2.9) 56 56 86 
Abbreviations: SR, Short-term remission (<2 years); LR, long-term remission (>2 years). 
aKruskal-Wallis Test: not significant P ≤ 0.05, statistically significant P ≤ 0.05, highly statistically 
significant P < 0.01. 
bNumber of samples with altered karyotypes in each of the stages. 
cTotal number of aberrations detected in the altered karyotypes (n/c = mean number of aberrations 
per altered karyotype). 
 
 
 
Table 5. Location of nonrandom chromosome alterations and correlation               
with fragile sites, oncogenes, and tumor suppressor genes 
Bands Fragile sites Oncogenes 
Tumor 
suppressor
genes 
1p13 — NRAS — 
1q25 FRA1G ARG, ABL2  
3p21 — TCTA, CTNNB1, AERB2 MLH1 
5q31-35 FRA5C IL-3, PDGFRB, CFS1R, NPM, FMS — 
6q21-23 FRA6F MYB, SYR, FYN, ROS1  
11p15 FRA11C HRAS, RBTN1, NUP98, MTACR1 KIP2, H19
12q13 FRA12A MDM2, INT1, GLI, CHOP, RARG, ERBB3, ATF1 — 
16q22-24 FRA16B CBFB, MAF  
17p13 FRA17A — TP53 
17q21 — CERBB2/NEU, RARA, AF17, NM23, NGL BRCA1 
 
 
 
 
 
 
 
 
 
Figure 1 Example of the karyotype of peripheral blood lymphocytes of a patient with 
an osteosarcoma obtained during treatment showing the complex pattern of aberrations. 
Case number 12 during treatment, Table 3:  
47,XY, del(1)(p22),t(2;11)(q11;p15),del(6)(q23),der(7)t(1;7)(q25;p15), +mar 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Ideogram showing chromosome breakpoints found in the samples at short-
term remission (left) and during chemotherapy regimens (right). 
 
 
 
 
 
 
 
 
 
Figure 3. Histogram showing the total number of chromosome gains and/or losses in 
the samples obtained during treatment. 
 
 
 
 
 
